Topivert’s topical kinase program brings in $28M in second round
By Nuala Moran
Friday, January 17, 2014
LONDON – Topivert Ltd. has raised £17 million (US$27.9 million) in a second funding round, providing the means to take its two lead topical kinase inhibitor programs to proof of concept and a hoped-for trade sale exit for the investors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.